What are the clinical manifestations, recommended investigations, and treatment options for Sturge-Weber syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sturge-Weber Syndrome: Clinical Manifestations, Investigations, and Treatment

Sturge-Weber syndrome (SWS) requires early neuroimaging with contrast-enhanced MRI after 1 year of age for definitive diagnosis, aggressive seizure control with antiepileptic medications, low-dose aspirin therapy, and regular ophthalmologic surveillance every 3 months during the first year to prevent vision-threatening complications.

Clinical Manifestations

Cutaneous Features

  • Facial port-wine birthmark (PWB) in the head/neck region, particularly involving the forehead, temple, or eyelids 1, 2
  • The location of the birthmark correlates with risk of brain and eye involvement
  • Facial asymmetry and gingival hyperplasia may develop 3

Neurological Manifestations

SWS presents with a spectrum of neurological complications 1, 4:

  • Seizures: Most common neurological manifestation, often drug-resistant epilepsy (DRE)
  • Stroke-like episodes: Due to impaired cerebral perfusion and venous stroke risk 5
  • Migraine headaches: Frequently reported
  • Cognitive deficits: Including intellectual disability and developmental delays
  • Motor difficulties: Related to brain involvement

Ophthalmologic Features

Eye involvement includes 6, 7:

  • Glaucoma: Most common ocular complication with bimodal onset
  • Diffuse choroidal hemangioma (DCH): Present in up to 87.5% when properly screened
  • Ocular vascular anomalies
  • Heterochromia of the iris
  • Visual field defects

Other Manifestations

  • Endocrine disorders (growth hormone deficiency, central hypothyroidism) 1
  • Elevated episcleral venous pressure contributing to glaucoma 6

Investigations

Neuroimaging Protocol

Timing is critical: Neuroimaging before 1 year of age has low sensitivity and may underestimate involvement; imaging after 1 year is necessary to exclude brain involvement 2.

MRI with and without contrast is the gold standard 2, 4:

  • Pathognomonic findings: Unilateral intracranial leptomeningeal angiomatosis (typically ipsilateral to facial birthmark) 1
  • Additional findings: Leptomeningeal enhancements, cortical calcifications, brain atrophy 2
  • Early detection marker: Choroid plexus (CP) thickness measurements have high sensitivity and specificity for early/incipient changes 4

Absence of pathologic findings allows for periodic observation with repeat imaging only if new clinical signs/symptoms develop 4.

Ophthalmologic Evaluation

Enhanced depth imaging spectral-domain optical coherence tomography (EDI-SDOCT) is superior to fundus photography 7:

  • EDI-SDOCT demonstrates 100% sensitivity and 100% accuracy for detecting DCH
  • Fundus photography has only 35.7% sensitivity and 43.8% accuracy
  • Near-infrared reflectance (NIR) imaging has 21.4% sensitivity
  • EDI-SDOCT enables early diagnosis even in pediatric cases with limited cooperation 7

Surveillance schedule 4:

  • Every 3 months during the first year
  • Yearly thereafter to monitor for glaucoma and choroidal hemangiomas

Genetic Testing

  • Somatic mosaic mutation in GNAQ gene (most common) 1, 2
  • Less commonly GNA11 or GNB2 mutations 4, 5
  • These are postzygotic, somatic, gain-of-function variants 4

Additional Studies

  • Quantitative EEG: May help identify abnormal electrical activity
  • Neuropsychological evaluation: To assess cognitive function and guide interventions 3

Treatment

Neurological Management

Seizure control is paramount 1, 2:

  • Aggressive antiepileptic medication therapy as first-line treatment
  • Presymptomatic treatment shows promise: Low-dose aspirin and antiepileptic drugs may delay seizure onset in at-risk infants 2, 5
  • Cannabidiol (CBD): Prospective trials support usefulness 5
  • Surgical options for drug-resistant epilepsy:
    • Limited surgical resection of epileptogenic tissue
    • Hemispherectomy in severe cases 1

Stroke prevention 5:

  • Low-dose aspirin: Retrospective studies suggest benefit in reducing frequency and severity of stroke-like events 5
  • Vitamin D supplementation: Emerging evidence supports use 5

Dermatologic Treatment

  • Pulsed dye laser using selective photo-thermolysis for port-wine birthmark 1
  • Treatment timing and modalities should be individualized based on birthmark characteristics 3

Ophthalmologic Management

Glaucoma treatment 6:

  • Medical management: ROCK inhibitors show good IOP control but require verification in larger populations
  • Surgical intervention: Non-penetrating procedures preferred due to safety profile and lower complication rates given anatomical abnormalities
  • Early detection and treatment crucial to preserve visual function 6

Emerging Therapies

Sirolimus (mTOR inhibitor) 4, 5:

  • Appears safe and potentially effective for cutaneous and extra-cutaneous features
  • Limited patient data; controlled clinical studies needed
  • Prospective trials show promising results 5

Multidisciplinary Care Requirements

Essential team members 3:

  • Dermatologist
  • Neurologist
  • Ophthalmologist
  • Neurosurgeon (for surgical candidates)
  • Maxillofacial surgeon
  • Dentist (for oral cavity assessment and gingival hyperplasia)
  • Neuropsychologist
  • Primary care physician for coordination

Critical Pitfalls to Avoid

  1. Do not rely on neuroimaging before 1 year of age to exclude brain involvement—sensitivity is too low 2
  2. Do not use fundus photography alone for DCH screening—87.5% of cases will be missed without EDI-SDOCT 7
  3. Do not delay ophthalmologic surveillance—glaucoma can develop early and cause irreversible vision loss 6
  4. Do not assume absence of facial PWB excludes SWS—diagnosis requires at least two of three features (facial capillary malformation, leptomeningeal malformation, ocular involvement) 3
  5. Do not perform endoscopy in epidermolysis bullosa patients (unrelated condition mentioned in evidence but not applicable to SWS)

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.